Trial Profile
A retrospective study to investigate efficacy and safety of Bortezomib in combination with Bendamustine and prednisone in patients with newly diagnosed or untreated multiple myeloma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2015
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Prednisone (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 07 Dec 2015 New trial record